DCM
CNTA

DAFNA Capital Management’s Centessa Pharmaceuticals CNTA Stock Holding History

DAFNA Capital Management’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-47,453
Closed -$795K – 87
2024
Q4 		$795K Sell
47,453
-72,898
-61% -$1.21M 0.2% 66
2024
Q3 		$1.92M Sell
120,351
-2,531
-2% -$31K 0.45% 47
2024
Q2 		$1.11M Buy
+122,882
New +$1.17M 0.27% 60

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DAFNA Capital Management's CNTA Position: Q1 2025 in Review

DAFNA Capital Management sold out of Centessa Pharmaceuticals (CNTA) in Q1 2025, closing a stake of 47,453 shares — an estimated $795K sold.

DAFNA Capital Management first reported a position in CNTA in Q2 2024 and held it in 3 quarters. The position peaked at $1.92M in Q3 2024. 129 funds tracked by Wall St. Rank hold CNTA as of Q1 2025.

  • DAFNA Capital Management reported no remaining Centessa Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • DAFNA Capital Management sold 47,453 Centessa Pharmaceuticals shares in Q1 2025, an estimated $795K.
  • DAFNA Capital Management first reported a position in Centessa Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • DAFNA Capital Management's Centessa Pharmaceuticals position peaked at $1.92M in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2025.

Based on DAFNA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.